← All organizations

Encysive

For profitContributed to NME

Also known as: Encysive Pharmaceuticals | Revotar Biopharmaceuticals AG | Texas Biotechnology Corporation

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 4

First clinical trial

Last known activity

Apr 21, 2010

Acquired by Pfizer on Jan 1, 2008

Timeline

1980s

Jan 1, 1989
Encysive— Founded

2000s

Jan 1, 2008
Pfizer— Acquired By

Drugs by trial phase (6 distinct, 9 trials)

Phase 4 (1 own, 0 via acquisition)

argatroban

Phase 3 (1 own, 0 via acquisition)

sitaxentan

Phase 2 (2 own, 0 via acquisition)

Phase 1 (2 own, 0 via acquisition)

Indications

Approved for

Studied for

Marketed drugs (1)

argatroban

Recent trials (9)

NCT01108913Lead sponsorPhase 2Apr 21, 2010
NCT00962481Lead sponsorPhase 2Aug 19, 2009
NCT00823693Lead sponsorPhase 2Jan 14, 2009
NCT01100736CollaboratorEarly Phase 1Jan 1, 2009
NCT00817037CollaboratorPhase 2May 1, 2007
NCT00039858Lead sponsorPhase 4Sep 1, 2003
NCT00080457Lead sponsorPhase 3May 1, 2003
NCT00035178Lead sponsorPhase 4May 1, 2002
NCT00034307CollaboratorPhase 2/Phase 3Apr 24, 2002

Details

Founded: Houston, TX, US Jan 1, 1989
Last known activity: Apr 21, 2010

Notes

--- Notes from Texas Biotechnology Corporation: Changed name to Encysive ---